Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 3Neutropenia 1Myelodysplastic Syndromes 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 28Etoposide 12Daunorubicin 11fludarabine phosphate 10Busulfan 10Peripheral Blood Stem Cell Transplantation 9tipifarnib 8Vorinostat 7Mitoxantrone 7Cyclosporine 7laromustine 6alvocidib 6Filgrastim 6Decitabine 6Cyclophosphamide 6Antilymphocyte Serum 6Idarubicin 5Methotrexate 4Bortezomib 4valspodar 3sargramostim 3romidepsin 3Radiotherapy 3Polymerase Chain Reaction 3Mycophenolic Acid 3Methylprednisolone 3Melphalan 3Gene Expression Profiling 3tanespimycin 2entinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Congenital Abnormalities × Amsacrine × Clear all
NCT00840684 2011-05-13

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
135 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡